Wednesday, February 21, 2024 Colorized transmission electron micrograph of HIV-1 virus particles (light orange) budding and replicating from an H9 T cell (blue/purple). The virus particles are in various stages of maturity, which accounts for differences in shape. Captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID Long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine was superior in suppressing HIV replication compared to daily oral ART in people who had been unable to maintain viral suppression through an oral daily regimen, according to interim data from a NIAID-sponsored randomized trial. Upon review of these findings, an independent Data and Safety Monitoring Board (DSMB) recommended halting randomization and inviting all eligible study participants to take long-acting ART. NIAID accepted the DSMB's recommendation. |
No comments:
Post a Comment